Similar articles for PMID: 27694386

Year	Number of Results
2007	1
2008	1
2009	6
2010	3
2011	3
2012	6
2013	9
2014	8
2015	6
2016	12
2017	16
2018	9
2019	11
2020	5
2021	8
2022	3
2023	4
2024	0

1

Acquired METD1228V Mutation and Resistance to MET Inhibition in Lung Cancer.

Bahcall M, Sim T, Paweletz CP, Patel JD, Alden RS, Kuang Y, Sacher AG, Kim ND, Lydon CA, Awad MM, Jaklitsch MT, Sholl LM, Jänne PA, Oxnard GR. Bahcall M, et al. Cancer Discov. 2016 Dec;6(12):1334-1341. doi: 10.1158/2159-8290.CD-16-0686. Epub 2016 Sep 30. Cancer Discov. 2016. PMID: 27694386 Free PMC article.

2

Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study.

Sequist LV, Han JY, Ahn MJ, Cho BC, Yu H, Kim SW, Yang JC, Lee JS, Su WC, Kowalski D, Orlov S, Cantarini M, Verheijen RB, Mellemgaard A, Ottesen L, Frewer P, Ou X, Oxnard G. Sequist LV, et al. Lancet Oncol. 2020 Mar;21(3):373-386. doi: 10.1016/S1470-2045(19)30785-5. Epub 2020 Feb 3. Lancet Oncol. 2020. PMID: 32027846 Clinical Trial.

3

Acquired Resistance Mechanisms to Combination Met-TKI/EGFR-TKI Exposure in Met-Amplified EGFR-TKI-Resistant Lung Adenocarcinoma Harboring an Activating EGFR Mutation.

Yamaoka T, Ohmori T, Ohba M, Arata S, Kishino Y, Murata Y, Kusumoto S, Ishida H, Shirai T, Hirose T, Ohnishi T, Sasaki Y. Yamaoka T, et al. Mol Cancer Ther. 2016 Dec;15(12):3040-3054. doi: 10.1158/1535-7163.MCT-16-0313. Epub 2016 Sep 9. Mol Cancer Ther. 2016. PMID: 27612490

4

Triple inhibition of EGFR, Met, and VEGF suppresses regrowth of HGF-triggered, erlotinib-resistant lung cancer harboring an EGFR mutation.

Nakade J, Takeuchi S, Nakagawa T, Ishikawa D, Sano T, Nanjo S, Yamada T, Ebi H, Zhao L, Yasumoto K, Matsumoto K, Yonekura K, Yano S. Nakade J, et al. J Thorac Oncol. 2014 Jun;9(6):775-83. doi: 10.1097/JTO.0000000000000170. J Thorac Oncol. 2014. PMID: 24828661 Free PMC article.

5

Met gene amplification and protein hyperactivation is a mechanism of resistance to both first and third generation EGFR inhibitors in lung cancer treatment.

Shi P, Oh YT, Zhang G, Yao W, Yue P, Li Y, Kanteti R, Riehm J, Salgia R, Owonikoko TK, Ramalingam SS, Chen M, Sun SY. Shi P, et al. Cancer Lett. 2016 Oct 1;380(2):494-504. doi: 10.1016/j.canlet.2016.07.021. Epub 2016 Jul 19. Cancer Lett. 2016. PMID: 27450722

6

MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib.

Bean J, Brennan C, Shih JY, Riely G, Viale A, Wang L, Chitale D, Motoi N, Szoke J, Broderick S, Balak M, Chang WC, Yu CJ, Gazdar A, Pass H, Rusch V, Gerald W, Huang SF, Yang PC, Miller V, Ladanyi M, Yang CH, Pao W. Bean J, et al. Proc Natl Acad Sci U S A. 2007 Dec 26;104(52):20932-7. doi: 10.1073/pnas.0710370104. Epub 2007 Dec 18. Proc Natl Acad Sci U S A. 2007. PMID: 18093943 Free PMC article.

7

Clinicopathologic and molecular features of epidermal growth factor receptor T790M mutation and c-MET amplification in tyrosine kinase inhibitor-resistant Chinese non-small cell lung cancer.

Chen HJ, Mok TS, Chen ZH, Guo AL, Zhang XC, Su J, Wu YL. Chen HJ, et al. Pathol Oncol Res. 2009 Dec;15(4):651-8. doi: 10.1007/s12253-009-9167-8. Epub 2009 Apr 21. Pathol Oncol Res. 2009. PMID: 19381876 Free article.

8

Combination therapy of erlotinib/crizotinib in a lung adenocarcinoma patient with primary EGFR mutation plus secondary MET amplification and a novel acquired crizotinib-resistant mutation MET G1108C.

Li YQ, Song SS, Jiang SH, Zhang XY. Li YQ, et al. Ann Oncol. 2017 Oct 1;28(10):2622-2624. doi: 10.1093/annonc/mdx324. Ann Oncol. 2017. PMID: 28961830 Free article. No abstract available.

9

Combination of BIBW2992 and ARQ 197 is effective against erlotinib-resistant human lung cancer cells with the EGFR T790M mutation.

Qu G, Liu C, Sun B, Zhou C, Zhang Z, Wang P. Qu G, et al. Oncol Rep. 2014 Jul;32(1):341-7. doi: 10.3892/or.2014.3178. Epub 2014 May 15. Oncol Rep. 2014. PMID: 24842595

10

Audit of Molecular Mechanisms of Primary and Secondary Resistance to Various Generations of Tyrosine Kinase Inhibitors in Known Epidermal Growth Factor Receptor-Mutant Non-small Cell Lung Cancer Patients in a Tertiary Centre.

Suryavanshi M, Jaipuria J, Mattoo S, Dhandha S, Khatri M. Suryavanshi M, et al. Clin Oncol (R Coll Radiol). 2022 Nov;34(11):e451-e462. doi: 10.1016/j.clon.2022.06.003. Epub 2022 Jul 7. Clin Oncol (R Coll Radiol). 2022. PMID: 35810049

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

101 results

Results by year